These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 20460057)
21. Systematic analysis of attenuated Coxsackievirus expressing a foreign gene as a viral vaccine vector. Kim DS; Cho YJ; Kim BG; Lee SH; Nam JH Vaccine; 2010 Feb; 28(5):1234-40. PubMed ID: 19941986 [TBL] [Abstract][Full Text] [Related]
22. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses. Fournillier A; Gerossier E; Evlashev A; Schmitt D; Simon B; Chatel L; Martin P; Silvestre N; Balloul JM; Barry R; Inchauspé G Vaccine; 2007 Oct; 25(42):7339-53. PubMed ID: 17875349 [TBL] [Abstract][Full Text] [Related]
23. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen. Martin P; Parroche P; Chatel L; Barretto C; Beck A; Trépo C; Bain C; Lone YC; Inchauspé G; Fournillier A J Med Virol; 2004 Nov; 74(3):397-405. PubMed ID: 15368525 [TBL] [Abstract][Full Text] [Related]
24. Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity. Rickard S; Ono SJ Exp Mol Pathol; 2008 Dec; 85(3):147-54. PubMed ID: 18952077 [TBL] [Abstract][Full Text] [Related]
25. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Haller AA; Lauer GM; King TH; Kemmler C; Fiolkoski V; Lu Y; Bellgrau D; Rodell TC; Apelian D; Franzusoff A; Duke RC Vaccine; 2007 Feb; 25(8):1452-63. PubMed ID: 17098335 [TBL] [Abstract][Full Text] [Related]
26. Viral peptide specific induction of MHC class II expression by murine T cell clones. Thomas DB; Smith CA; Graham CM J Immunol; 1996 Sep; 157(6):2386-94. PubMed ID: 8805637 [TBL] [Abstract][Full Text] [Related]
27. Mutation of the invariant chain transmembrane region inhibits II degradation, prolongs association with MHC class II, and selectively disrupts antigen presentation. Frauwirth K; Shastri N Cell Immunol; 2001 May; 209(2):97-108. PubMed ID: 11446742 [TBL] [Abstract][Full Text] [Related]
28. [A study on the inhibitory effect on transplanted tumor growth expressing HCV NS3 protein by HCV minigene vaccine based on invariant chain substitution in mice]. Gao M; Wang HP; Zhou Y; Wang JJ; Wang YN; Wang QL Zhonghua Gan Zang Bing Za Zhi; 2005 Nov; 13(11):801-4. PubMed ID: 16313719 [TBL] [Abstract][Full Text] [Related]
29. Use of conventional or replicating nucleic acid-based vaccines and recombinant Semliki forest virus-derived particles for the induction of immune responses against hepatitis C virus core and E2 antigens. Vidalin O; Fournillier A; Renard N; Chen M; Depla E; Boucreux D; Brinster C; Baumert T; Nakano I; Fukuda Y; Liljeström P; Trépo C; Inchauspé G Virology; 2000 Oct; 276(2):259-70. PubMed ID: 11040118 [TBL] [Abstract][Full Text] [Related]
31. Low dose and gene gun immunization with a hepatitis C virus nonstructural (NS) 3 DNA-based vaccine containing NS4A inhibit NS3/4A-expressing tumors in vivo. Frelin L; Alheim M; Chen A; Söderholm J; Rozell B; Barnfield C; Liljeström P; Sällberg M Gene Ther; 2003 Apr; 10(8):686-99. PubMed ID: 12692597 [TBL] [Abstract][Full Text] [Related]
32. Identification of residues in the class II-associated Ii peptide (CLIP) region of invariant chain that affect efficiency of MHC class II-mediated antigen presentation in an allele-dependent manner. Gautam AM; Yang M; Milburn PJ; Baker R; Bhatnagar A; McCluskey J; Boston T J Immunol; 1997 Sep; 159(6):2782-8. PubMed ID: 9300699 [TBL] [Abstract][Full Text] [Related]
34. [Development of hepatitis C virus vaccine]. Matsuura Y; Ishii K; Suzuki T; Miyamura T Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):112-6. PubMed ID: 7563667 [No Abstract] [Full Text] [Related]
35. What's next for hepatitis C virus research? Lindenbach BD Hepatology; 2016 May; 63(5):1408-10. PubMed ID: 26853717 [No Abstract] [Full Text] [Related]
36. Unique approach for B lymphoma therapy. Epstein AL Blood; 2012 Apr; 119(16):3647-8. PubMed ID: 22517869 [No Abstract] [Full Text] [Related]
37. Progress in the development of hepatitis C virus vaccines. Ertl HC Mol Ther; 2012 Apr; 20(4):697-8. PubMed ID: 22472980 [No Abstract] [Full Text] [Related]
38. Following Europe's lead, Congress moves to ban ape research. Hutson S Nat Med; 2010 Oct; 16(10):1057. PubMed ID: 20930731 [No Abstract] [Full Text] [Related]
39. [Construction of hepatitis C virus-NS3 Th1 plasmid vaccine based on MHC class II-associated invariant chain peptide substitution]. Gao M; Wang HP; Lu Y; Zhou Y; Wang YN; Zhan LS; Wang QL Zhonghua Gan Zang Bing Za Zhi; 2010 Apr; 18(4):309-10. PubMed ID: 20460057 [No Abstract] [Full Text] [Related]
40. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain. Mikkelsen M; Holst PJ; Bukh J; Thomsen AR; Christensen JP J Immunol; 2011 Feb; 186(4):2355-64. PubMed ID: 21257961 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]